JAAD International最新文献

{"title":"Hidradenitis suppurativa electronic medical record (EPIC) tool: A convenient Tool for hidradenitis suppurativa specialty clinics","authors":"Zachary Wendland MD, MPH , Katelyn J. Rypka MD , Lindsey Greenlund MD , Claire Herzog MD , Bisma Khalid MBBS , Jennifer Steinhaus RN, BSN, PHN, MS , Noah Goldfarb MD","doi":"10.1016/j.jdin.2024.09.020","DOIUrl":"10.1016/j.jdin.2024.09.020","url":null,"abstract":"","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"19 ","pages":"Pages 83-85"},"PeriodicalIF":0.0,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143552851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antidesmoglein 1 and 3 serum IgG and positivity by direct immunofluorescence microscopy is associated with relapse in pemphigus in a prospective bicontinental study","authors":"Dipankar De MD ,&nbsp;Shipla Shilpa MSc ,&nbsp;Sheetanshu Kumar MD ,&nbsp;Kossara Drenovska MD, PhD ,&nbsp;Hitaishi Mehta MD ,&nbsp;Nina van Beek MD ,&nbsp;Naresh Sachdeva PhD ,&nbsp;Alexandra Fleva PhD ,&nbsp;Martin Shahid MD, PhD ,&nbsp;Sanjeev Handa MD ,&nbsp;Anastasia Giannakou MD ,&nbsp;Elissaveta Naumova MD, PhD, DSci ,&nbsp;Rahul Mahajan MD ,&nbsp;Aikaterini Kyriakou MD ,&nbsp;Spaska Lesichkova MD ,&nbsp;Elisabeth Lazaridou MD, PhD ,&nbsp;Bishan Dass Radotra MD, PhD ,&nbsp;Kamal Kishore PhD ,&nbsp;Snejina Vassileva MD, PhD ,&nbsp;Aikaterini Patsatsi MD, PhD ,&nbsp;Enno Schmidt MD, PhD","doi":"10.1016/j.jdin.2024.12.004","DOIUrl":"10.1016/j.jdin.2024.12.004","url":null,"abstract":"<div><h3>Background</h3><div>Prospective studies identifying immunological parameters that can predict clinical relapse in pemphigus are scarce.</div></div><div><h3>Objective</h3><div>To periodically assess immunological parameters in patients with pemphigus vulgaris and foliaceous in remission to understand immunological events preceding clinical relapse.</div></div><div><h3>Methods</h3><div>A total of 105 patients were included. Baseline assessment included direct immunofluorescence (DIF), serum IgG against desmoglein (Dsg) 1, IgG, IgG1, and IgG4 against Dsg 3, IgG against the extracellular domains 1 and 2 of Dsg 3, IgG against muscarinic (M3)-AchR, and peripheral CD19+CD27+ memory B cells/plasma cells, repeated every 3 months for up to 12 months or until clinical relapse. DIF was repeated at month 12 and on relapse.</div></div><div><h3>Results</h3><div>About 29 of 105 patients (28%) experienced a relapse. Longer duration of clinical remission, presence of pruritus and positive anti-Dsg1 at baseline correlated with higher relapse rates. Compared with the visit immediately preceding relapse, a significantly increased number of patients with positive anti-Dsg1 (38% vs 31.1%, <em>P</em> = .01), anti-Dsg3 (51.7% vs 41.4%, <em>P</em> = .01) and IgG positivity by DIF (85.7% vs 25%, <em>P</em> &lt; .001) was observed at the time of relapse.</div></div><div><h3>Conclusion</h3><div>Regular monitoring of anti-Dsg 1 and anti-Dsg 3 serum levels and DIF positivity during the course of the disease in remission may predict relapse.</div></div>","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"19 ","pages":"Pages 67-74"},"PeriodicalIF":0.0,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143463681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of CO2 laser with computerized scanner in the treatment of recalcitrant plantar warts: A retrospective case series","authors":"Ko Kagoyama MD,&nbsp;Teruhiko Makino MD, PhD,&nbsp;Tadamichi Shimizu MD, PhD","doi":"10.1016/j.jdin.2024.12.003","DOIUrl":"10.1016/j.jdin.2024.12.003","url":null,"abstract":"","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"19 ","pages":"Pages 60-61"},"PeriodicalIF":0.0,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143453170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bicalutamide 25 mg combined with minoxidil 1 mg versus minoxidil 1 mg for female pattern hair loss: A randomized double-blind clinical trial","authors":"Ricardo da Silva Libório MD ,&nbsp;Adriana Viana da Motta MD ,&nbsp;Hélio Amante Miot MD, PhD ,&nbsp;Paulo Müller Ramos MD, PhD","doi":"10.1016/j.jdin.2024.12.002","DOIUrl":"10.1016/j.jdin.2024.12.002","url":null,"abstract":"<div><h3>Background</h3><div>Antiandrogenic drugs are often used to treat female pattern hair loss (FPHL) despite limited evidence supporting their use. There is growing interest in bicalutamide for this purpose, but its efficacy in treating FPHL has not been evaluated in clinical trials.</div></div><div><h3>Objectives</h3><div>To assess the efficacy of 25 mg/d bicalutamide combined with 1 mg/d minoxidil compared to 1 mg/d minoxidil monotherapy over 24 weeks for FPHL treatment.</div></div><div><h3>Methods</h3><div>A randomized, controlled, double-blind clinical trial enrolled 74 participants into 2 groups: bicalutamide 25 mg/d plus minoxidil 1 mg/d or placebo plus minoxidil 1 mg/d for 24 weeks. The primary outcome was the change in total hair density in the target area.</div></div><div><h3>Result</h3><div>Sixty-four (86.5%) participants completed the study (32 per group). There was a mean increase of 18.1 hairs/cm² in the bicalutamide-minoxidil group and 21.5 hairs/cm² in the minoxidil group (<em>P</em> = .86). According to the global consensus analysis of clinical photographs, there was no difference in clinical improvement between the groups (<em>P</em> = .78).</div></div><div><h3>Limitations</h3><div>Single-center study and short follow-up period (24 weeks).</div></div><div><h3>Conclusion</h3><div>Bicalutamide 25 mg/d combined with minoxidil 1 mg/d did not provide additional improvement in FPHL treatment compared to minoxidil alone after 24 weeks.</div></div>","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"19 ","pages":"Pages 48-55"},"PeriodicalIF":0.0,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143402816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of postburn hypertrophic scaring in skin of color with fractional CO2 laser - A prospective cohort study","authors":"Samman Khalid MBBS ,&nbsp;Bianca Sanabria MA ,&nbsp;Isabella Tan BS ,&nbsp;Samavia Khan MD ,&nbsp;Husnain Khan FCPS ,&nbsp;Babar Rao MD","doi":"10.1016/j.jdin.2025.01.001","DOIUrl":"10.1016/j.jdin.2025.01.001","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the efficacy of fractional CO2 laser therapy in treating mature hypertrophic burn scars.</div></div><div><h3>Method</h3><div>A prospective cohort study enrolled burn patients with postburn hypertrophic scars undergoing fractional CO2 laser treatment in Rawalpindi, Pakistan. Patients aged 12 to 80 years were included, receiving 4 laser sessions every 4-6 weeks. Demographic data and scar assessments using the Vancouver Scar Scale and Patient Observer Scar Assessment Scale were collected.</div></div><div><h3>Results</h3><div>Twenty-five patients with hypertrophic scars received treatment. Vancouver Scar Scale scores showed significant reductions, with improvements in scar vascularity (pre: 0.85 ± 1.085, post: 0.10 ± 0.300, <em>P</em> &lt; .001), pigmentation (pre: 2.44 ± 0.673, post: 2.12 ± 0.900, <em>P</em> = .008), and pliability (pre: 2.29 ± 1.078, post: 1.39 ± 0.997, <em>P</em> &lt; .001). Patients with Fitzpatrick skin types III and IV had notable Vancouver Scar Scale score improvements (<em>P</em> = .013, <em>P</em> &lt; .001). Patient Observer Scar Assessment Scale scores also decreased significantly post-treatment (<em>P</em> &lt; .001).</div></div><div><h3>Conclusion</h3><div>Fractional CO2 laser therapy shows promise in managing mature hypertrophic burn scars, with improvement in scar appearance, functionality, and symptom relief. Stratification by Fitzpatrick skin type highlights the need for further research to optimize treatment strategies, particularly in populations with darker skin tones. This study underscores the importance of further longitudinal studies on burn scars to enhance outcomes for all burn survivors.</div></div>","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"19 ","pages":"Pages 35-42"},"PeriodicalIF":0.0,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143145754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and histopathologic characteristics and outcomes of cellular dermatofibroma: A retrospective observational study of 29 patients","authors":"Nicholas T. Le BS ,&nbsp;Daniel B. Eisen MD","doi":"10.1016/j.jdin.2024.12.001","DOIUrl":"10.1016/j.jdin.2024.12.001","url":null,"abstract":"","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"19 ","pages":"Pages 43-44"},"PeriodicalIF":0.0,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143145755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Histologic absence of yeast as a clue for classic lichen planopilaris, fibrosing alopecia in a pattern distribution, and frontal fibrosing alopecia: A cross-sectional observational study","authors":"Kimberly Williams BS ,&nbsp;Antonella Tosti MD ,&nbsp;Curtis T. Thompson MD","doi":"10.1016/j.jdin.2024.11.008","DOIUrl":"10.1016/j.jdin.2024.11.008","url":null,"abstract":"","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"19 ","pages":"Pages 10-11"},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11763523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143053551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weight gain secondary to the use of oral Janus kinase inhibitors: A systematic review and meta-analysis","authors":"Grace Xiong BHSc ,&nbsp;Eric Yu ,&nbsp;Martin Heung ,&nbsp;Jaehyeong Yang BSc ,&nbsp;Megan Lowe MPH ,&nbsp;Mohannad Abu-Hilal MD","doi":"10.1016/j.jdin.2024.11.009","DOIUrl":"10.1016/j.jdin.2024.11.009","url":null,"abstract":"<div><div>Oral Janus kinase inhibitors (JAKi) are increasingly used in dermatology, rheumatology, gastroenterology, and hematology. While effective, they can cause adverse effects such as acne, nausea, cytopenia, dyslipidemia, and Herpes zoster. Recent reports have linked JAKi usage to weight changes, particularly weight gain, which can significantly impact patients' quality of life. This study aimed to describe the incidence and characteristics of weight changes associated with the use of JAKi. Ovid MEDLINE, Embase, Web of Science, and Clinicaltrials.gov were searched up to April 2024. From 1080 initial articles, 90 studies covering 16,000 patients were selected. Our analysis found a notable incidence of weight gain with JAKi usage. Overall, 5.9% (947/16,000) of patients reported weight again. In randomized control trials, weight gain was observed in 7% (95% CI: 0.04; 0.09) of patients, while weight loss was observed in 1% (95% CI: 0.00; 0.03). Patients with dermatologic indications had lower weight gain rates (4%, 95% CI: 0.01; 0.06) than those with nondermatological indications (7%, 95% CI: 0.04; 0.10). Overall, JAKi therapy is associated with weight changes, particularly weight gain, underscoring the importance of appropriate counseling and weight monitoring. Further long-term studies are needed to better understand the mechanisms and management of JAKi-related weight changes.</div></div>","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"19 ","pages":"Pages 1-9"},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11763511/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143053602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cutaneous complications to medical adhesives in left ventricular assist device patients: A retrospective cohort study","authors":"Brenda Umenita Akinniyi MS ,&nbsp;Hala Rogers MD ,&nbsp;Shawn Glocker BS ,&nbsp;Farooq H. Sheikh MD ,&nbsp;Michael A. Cardis MD","doi":"10.1016/j.jdin.2024.11.007","DOIUrl":"10.1016/j.jdin.2024.11.007","url":null,"abstract":"","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"19 ","pages":"Pages 33-34"},"PeriodicalIF":0.0,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143144880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atopic dermatitis in childhood and pubertal development: A nationwide cohort study","authors":"Camilla Lomholt Kjersgaard MD ,&nbsp;Andreas Ernst MD, PhD ,&nbsp;Pernille Jul Clemmensen MD, PhD ,&nbsp;Lea Lykke Harrits Lunddorf MD, PhD ,&nbsp;Linn Håkonsen Arendt MD, PhD ,&nbsp;Nis Brix MD, PhD ,&nbsp;Onyebuchi A. Arah MD, PhD ,&nbsp;Mette Deleuran MD, PhD ,&nbsp;Cecilia Høst Ramlau-Hansen MHSc, PhD","doi":"10.1016/j.jdin.2024.09.018","DOIUrl":"10.1016/j.jdin.2024.09.018","url":null,"abstract":"<div><h3>Background</h3><div>Atopic dermatitis (AD) might delay puberty, but research is lacking.</div></div><div><h3>Objective</h3><div>To investigate the association between AD and puberty.</div></div><div><h3>Methods</h3><div>A subcohort within the Danish National Birth Cohort includes children born between 2000 and 2003, with mothers reporting doctor-diagnosed AD at 6 months, 18 months, and 7 years old. The National Patient Registry identified hospital-diagnosed AD. From 11 years, the children give half-yearly information on pubertal development. We estimated the mean age difference in months at attaining Tanner stages 1 to 5 and the development of axillary hair, acne, first ejaculation, voice break, and age at menarche, using an interval-censored regression model.</div></div><div><h3>Results</h3><div>In total, 15,534 children participated, 21.5% had self-reported doctor-diagnosed AD and 0.7% had hospital-diagnosed AD. For girls with self-reported doctor-diagnosed AD, the average age difference at reaching all pubertal milestones was 0.0 months (95% confidence interval [CI]: −0.8; 0.8), and for hospital-diagnosed AD, it was −0.3 months (95% CI: −5.4; 4.8). For boys, the average age difference was 0.1 months (95% CI: −0.6; 0.9) and −0.3 months (95% CI: −3.6; 3.0), respectively.</div></div><div><h3>Limitations</h3><div>No information on treatment was available. Missing data on covariates (&lt;5%) were not addressed.</div></div><div><h3>Conclusion</h3><div>No association was found between AD and puberty in either girls or boys.</div></div>","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"19 ","pages":"Pages 21-31"},"PeriodicalIF":0.0,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11787039/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}